Background Data on the effectiveness of oral antivirals in patients with mild-to-moderate
COVID-19 are urgently needed. This retrospective cohort study aimed to evaluate the …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

Background: Whether hospitalized patients benefit from COVID-19 oral antivirals is
uncertain. Objective: To examine the real-world effectiveness of molnupiravir and …

Background Viral rebound after nirmatrelvir–ritonavir treatment has implications for the
clinical management and isolation of patients with COVID-19. We evaluated an unselected …

Background Real-world data is currently limited on the association between oral antiviral
therapy and healthcare system burden in patients with mild-to-moderate COVID-19. This …

Background We examined the effectiveness of molnupiravir and nirmatrelvir/ritonavir in
reducing hospitalization and deaths in a real-world cohort of nonhospitalized patients with …

Background Nirmatrelvir is a protease inhibitor with in-vitro activity against SARS-CoV-2,
and ritonavir-boosted nirmatrelvir can reduce the risk of progression to severe COVID-19 …

Background The real-world effectiveness of molnupiravir (MOL) during the dominance of
Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the …

Background: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in
hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical …

Background In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12
years or older with mild-to-moderate COVID-19 who are at risk of progression to severe …